Clinical Trials Logo

Clinical Trial Summary

In a population of patients with non-valvular atrial fibrillation (NVAF), and treated with oral anticoagulants (OAC) in routine clinical practice in England, this study will describe patients treated with each OAC, and to estimate and compare event rates of treatment discontinuation, bleeding, and healthcare resource utilisation (HCRU) across OAC treatments.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03002740
Study type Observational
Source Bristol-Myers Squibb
Status Withdrawn
Start date January 31, 2016
Completion date August 31, 2018

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Active, not recruiting NCT03087487 - Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
Active, not recruiting NCT03508258 - Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)
Terminated NCT03715725 - A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Completed NCT02756481 - Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela N/A
Active, not recruiting NCT04193826 - The Conformal Prague Study N/A
Completed NCT01884350 - Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) Phase 4
Completed NCT02422602 - Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program N/A
Recruiting NCT02147444 - Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation N/A
Completed NCT01857622 - Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment Phase 3
Recruiting NCT04829929 - Evaluation od Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk N/A
Completed NCT03570047 - Safety and Effectiveness of Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation
Active, not recruiting NCT03204695 - WAVECREST Post Market Clinical Follow-Up (PMCF) Study Phase 3
Active, not recruiting NCT04722679 - A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.
Completed NCT04297072 - Study to Gather Information on the Kidney Function of Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) Treated With Rivaroxaban or Vitamin K Antagonists
Recruiting NCT03088072 - A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure Phase 4
Recruiting NCT04519944 - Edoxaban in Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Completed NCT02488421 - Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2 N/A
Recruiting NCT04096963 - Observe the Safety and Effectiveness of the WATCHMAN FLX™ for Subjects in Hong Kong
Recruiting NCT02222090 - Therapy With New Oral Anticoagulants N/A